Can osimertinib cure non-small cell lung cancer?

Osimertinib (generic name: osimertinib mesylate) is indeed used to treat non-small cell lung cancer (NSCLC), but whether it can "cure" non-small cell lung cancer needs to be evaluated on a case-by-case basis.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor, mainly used to treat patients with non-small cell lung cancer carrying EGFR sensitive mutations. It inhibits the proliferation and growth of tumor cells by selectively inhibiting the activity of EGFR tyrosine kinase and blocking the EGFR signaling pathway. Multiple clinical studies have confirmed that osimertinib can significantly extend the progression-free survival (PFS) and overall survival (OS) of patients with non-small cell lung cancer.

Osimertinib is mainly suitable for patients with two types of non-small cell lung cancer:

First-line treatment: Suitable for patients with locally advanced or metastatic non-small cell lung cancer with EGFRexon19 deletion or exon 21 (L858R) substitution mutation.

Second-line treatment: Applicable to patients with locally advanced or metastatic non-small cell lung cancer who have previously received EGFRtyrosine kinase inhibitors (TKI) and have disease progression during or after treatment, and are confirmed to have EGFR T790M mutation-positive patients.

Can“Cure” non-small cell lung cancer

Although osimertinib has achieved significant efficacy in the treatment of non-small cell lung cancer,The word "cure" needs to be used with caution. According to authoritative medical institutions, there is currently no drug that can claim to "cure" cancer, including non-small cell lung cancer. Osimertinib can prolong patient survival and improve quality of life, but it cannot guarantee complete elimination of cancer cells or prevent disease recurrence.

The treatment effect of non-small cell lung cancer is affected by many factors, including but not limited to:

Stage and type of tumor: Early-stage tumors are usually easier to treat than late-stage tumors.

The patient's overall health status: including age, physical status, comorbidities, etc.

EGFRMutation status: Patients with EGFR sensitizing mutations generally respond better to osimertinib.

Individual differences: Different patients have different sensitivity and tolerance to drugs.